Compare TG Therapeutics Inc (TGTX) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vipshop Holdings Ltd - ADR — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Vipshop Holdings Ltd - ADR trades at $15.06 (market cap $7.20B). The key difference: TG Therapeutics Inc and Vipshop Holdings Ltd - ADR are close in size by market cap, and Vipshop Holdings Ltd - ADR pays a 4.14% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | VIPS | |
|---|---|---|
Market Cap | $7.64B | $7.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $20.68 |
52-Week Low | $26.94 | $12.92 |
Enterprise Value | $7.84B | $3.76B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Vipshop (VIPS) trades at $14.49, down 5.97% over 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The stock shows attractive valuation metrics, including a P/E of 6.79 and P/S of 0.48, alongside strong profitability with an 18.43% ROE. Recent earnings have been mixed, with Q1 2026 EPS meeting expectations, while the company pursues growth through an outlet strategy and REIT spin-off.
The outlook remains positive due to low valuations and profitability, but risks include revenue stagnation and competitive pressures. Analyst consensus is bullish with 53.57% buy ratings, supporting potential upside if earnings growth resumes in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
